Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection

COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts...

Descripción completa

Detalles Bibliográficos
Autores principales: Landi, Doriana, Cola, Gaia, Mantero, Vittorio, Balgera, Roberto, Moiola, Lucia, Nozzolillo, Agostino, Dattola, Vincenzo, Sinisi, Leonardo, Fantozzi, Roberta, Di Lemme, Sonia, Centonze, Diego, Mataluni, Giorgia, Nicoletti, Carolina Gabri, Marfia, Girolama Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542399/
https://www.ncbi.nlm.nih.gov/pubmed/35158454
http://dx.doi.org/10.1016/j.msard.2021.103345
Descripción
Sumario:COVID-19 pandemic represented a challenge in the management of treatments for Multiple Sclerosis (MS), such as Natalizumab (NTZ). NTZ interferes with the homing of lymphocytes into the central nervous system, reducing immune surveillance against opportunistic infection. Although NTZ efficacy starts to decline 8 weeks after the last infusion, increasing the risk of disease reactivation, evidence is lacking on the safety of reinfusion during active SARS-CoV-2 infection. We report clinical outcomes of 18 pwMS receiving NTZ retreatment during confirmed SARS-CoV-2 infection. No worsening of infection or recovery delay was observed. Our data supports the safety of NTZ redosing in these circumstances.

Ejemplares similares